Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult with B-ALL in MRD⁻ remission?

During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the ALL Hub was pleased to speak to Mark R. Litzow, Mayo Clinic, Rochester, US. We asked, Does consolidation therapy with blinatumomab improve survival in newly diagnosed adult patients with B-ALL in MRD⁻ remission?

Litzow provides an update on the results from the ECOG-ACRIN E1910 randomized phase III trial of blinatumomab on behalf of the National Cooperative Clinical Trial Network. He then discusses how the addition of blinatumomab to consolidation chemotherapy can improve overall survival in patients with newly diagnosed B-ALL who were MRD-negative after intensification chemotherapy without any safety concerns. He concludes that the addition of blinatumomab to consolidation chemotherapy represents a new standard of care for adult patients with MRD-negative B-ALL.